Clinical evidence supporting cefiderol for serious Acinetobacter baumannii infections.
Journal
Current opinion in infectious diseases
ISSN: 1473-6527
Titre abrégé: Curr Opin Infect Dis
Pays: United States
ID NLM: 8809878
Informations de publication
Date de publication:
01 12 2022
01 12 2022
Historique:
entrez:
8
11
2022
pubmed:
9
11
2022
medline:
10
11
2022
Statut:
ppublish
Résumé
Nosocomial infections caused by Acinetobacter baumannii currently represent a serious challenge for clinicians because treatment options are limited and frequently associated with significant toxicity. Cefiderocol is a first-in-class siderophore cephalosporin that has a proven efficacy for the treatment of multidrug-resistant Gram-negative infections, including carbapenem-resistant A. baumannii. The aim of this review is to evaluate the current evidence for the role of cefiderocol in the management of A. baumannii infections. In this review, we briefly summarize the available data on the efficacy (from randomized controlled trials) and on effectiveness and cure rates (from observational studies), pertaining to the use of cefiderocol for treatment of serious A. baumannii infections. Cefiderocol represents a promising and safe antibiotic option for treating patients with carbapenem-resistant A. baumannii infections. Due to conflicting mortality data from available experience, well-designed future randomized controlled trials and real-life studies are needed.
Identifiants
pubmed: 36345852
doi: 10.1097/QCO.0000000000000880
pii: 00001432-202212000-00009
doi:
Substances chimiques
Cephalosporins
0
Carbapenems
0
Anti-Bacterial Agents
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
545-551Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Bassetti M, Labate L, Russo C, et al. Therapeutic options for difficult-to-treat Acinetobacter baumannii infections: a 2020 perspective. Expert Opin Pharmacother 2021; 22:167–177.
Harding CM, Hennon SW, Feldman MF. Uncovering the mechanisms of Acinetobacter baumannii virulence. Nat Rev Microbiol 2018; 16:91–102.
Chen Z, Chen Y, Fang Y, et al. Meta-analysis of colistin for the treatment of Acinetobacter baumannii infection. Sci Rep 2015; 5:17091.
Kempf M, Djouhri-Bouktab L, Brunel JM, et al. Synergistic activity of sulbactam combined with colistin against colistin-resistant Acinetobacter baumannii. Int J Antimicrob Agents 2012; 39:180–181.
Kengkla K, Kongpakwattana K, Saokaew S, et al. Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis. J Antimicrob Chemother 2018; 73:22–32.
Panidis D, Markantonis SL, Boutzouka E, et al. Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia. Chest 2005; 128:545–552.
Hua X, Li C, Pogue JM, et al. ColistinDose, a mobile app for determining intravenous dosage regimens of colistimethate in critically ill adult patients: clinician-centered design and development study. JMIR Mhealth Uhealth 2020; 8:e20525.
Tiseo G, Brigante G, Giacobbe DR, et al. Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical Microbiologists (AMCLI) and the Italian Society of Microbiology (SIM). Int J Antimicrob Agents 2022; 60:106611.
Lawandi A, Yek C, Kadri SS. Infectious Diseases Society of America (IDSA) guidance and ESCMID guidelines: complementary approaches toward a care standard for MDR Gram-negative infections. Clin Microbiol Infect 2022; 28:465–469.
Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America Guidance on the Treatment of AmpC beta-lactamase-producing enterobacterales, carbapenem-resistant acinetobacter baumannii, and Stenotrophomonas maltophilia infections. Clin Infect Dis 2022; 74:2089–2114.
Paul M, Carrara E, Retamar P, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect 2022; 28:521–547.
Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis 2018; 18:391–400.
Aydemir H, Akduman D, Piskin N, et al. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect 2013; 141:1214–1222.
Ong’uti S, Czech M, Robilotti E, Holubar M. Cefiderocol: a new cephalosporin stratagem against multidrug-resistant gram-negative bacteria. Clin Infect Dis 2022; 74:1303–1312.
Portsmouth S, van Veenhuyzen D, Echols R, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, noninferiority trial. Lancet Infect Dis 2018; 18:1319–1328.
Wunderink RG, Matsunaga Y, Ariyasu M, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, noninferiority trial. Lancet Infect Dis 2021; 21:213–225.
Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis 2021; 21:226–240.
Falcone M, Tiseo G, Leonildi A, et al. Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2022; 66:e0214221.
Pascale R, Pasquini Z, Bartoletti M, et al. Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study. JAC Antimicrob Resist 2021; 3:dlab174.
Bavaro DF, Belati A, Diella L, et al. Cefiderocol-based combination therapy for ‘difficult-to-treat’ gram-negative severe infections: real-life case series and future perspectives. Antibiotics (Basel) 2021; 10:652.
Rose L, Lai L, Byrne D. Successful prolonged treatment of a carbapenem-resistant Acinetobacter baumannii hip infection with cefiderocol: a case report. Pharmacotherapy 2022; 42:268–271.
Zaidan N, Hornak JP, Reynoso D. Extensively drug-resistant acinetobacter baumannii nosocomial pneumonia successfully treated with a novel antibiotic combination. Antimicrob Agents Chemother 2021; 65:e0092421.
Cipko K, Kizny Gordon A, Adhikari S, Konecny P. Cefiderocol treatment of Pseudomonas aeruginosa and extensively drug-resistant Acinetobacter baumannii retained spinal hardware infection causing reversible acute interstitial nephritis: Recto: Cefiderocol causing acute interstitial nephritis. Int J Infect Dis 2021; 109:108–111.
Oliva A, Ceccarelli G, De Angelis M, et al. Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant Acinetobacter baumannii. J Glob Antimicrob Resist 2020; 23:292–296.
Mabayoje DA, NicFhogartaigh C, Cherian BP, et al. Compassionate use of cefiderocol for carbapenem-resistant Acinetobacter baumannii prosthetic joint infection. JAC Antimicrob Resist 2021; 3:i21–i24.
Dagher M, Ruffin F, Marshall S, et al. Case report: successful rescue therapy of extensively drug-resistant acinetobacter baumannii osteomyelitis with cefiderocol. Open Forum Infect Dis 2020; 7:ofaa150.
Trecarichi EM, Quirino A, Scaglione V, et al. Successful treatment with cefiderocol for compassionate use in a critically ill patient with XDR Acinetobacter baumannii and KPC-producing Klebsiella pneumoniae: a case report. J Antimicrob Chemother 2019; 74:3399–3401.
Karlowsky JA, Hackel MA, Takemura M, et al. In vitro susceptibility of gram-negative pathogens to cefiderocol in five consecutive annual multinational SIDERO-WT surveillance studies, 2014 to 2019. Antimicrob Agents Chemother 2022; 66:e0199021.
Shortridge D, Streit JM, Mendes R, Castanheira M. In vitro activity of cefiderocol against U.S. and European Gram-negative clinical isolates collected in 2020 as part of the SENTRY antimicrobial surveillance program. Microbiol Spectr 2022; 10:e0271221.
Simner PJ, Patel R. Cefiderocol antimicrobial susceptibility testing considerations: the Achilles’ heel of the trojan horse? J Clin Microbiol 2020; 59:e00951-20.
Rolston KVI, Gerges B, Shelburne S, et al. Activity of cefiderocol and comparators against isolates from cancer patients. Antimicrob Agents Chemother 2020; 64:e01955-19.
Golden AR, Adam HJ, Baxter M, et al. In vitro activity of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacilli isolated from patients in Canadian intensive care units. Diagn Microbiol Infect Dis 2020; 97:115012.
Monogue ML, Tsuji M, Yamano Y, et al. Efficacy of humanized exposures of cefiderocol (S-649266) against a diverse population of Gram-negative bacteria in a murine thigh infection model. Antimicrob Agents Chemother 2017; 61:e01022-17.
Matsumoto S, Singley CM, Hoover J, et al. Efficacy of cefiderocol against carbapenem-resistant Gram-negative bacilli in immunocompetent-rat respiratory tract infection models recreating human plasma pharmacokinetics. Antimicrob Agents Chemother 2017; 61:e00700-17.
Stainton SM, Monogue ML, Tsuji M, et al. Efficacy of humanized cefiderocol exposures over 72 hours against a diverse group of Gram-negative isolates in the neutropenic murine thigh infection model. Antimicrob Agents Chemother 2019; 63:e01040-18.
Abdul-Mutakabbir JC, Nguyen L, Maassen PT, et al. In vitro antibacterial activity of cefiderocol against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2021; 65:e0264620.
Lodise TP, Bassetti M, Ferrer R, et al. All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies. Expert Rev Anti Infect Ther 2022; 20:707–719.
Heil EL, Tamma PD. Cefiderocol: the Trojan horse has arrived but will Troy fall? Lancet Infect Dis 2021; 21:153–155.
Falcone M, Tiseo G, Nicastro M, et al. Cefiderocol as rescue therapy for acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in intensive care unit patients. Clin Infect Dis 2021; 72:2021–2024.